Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).

Details

Ressource 1Download: serval:BIB_DF41C34D3C27.P001 (148.51 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_DF41C34D3C27
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Journal
Annals of Oncology
Author(s)
Zaman K., Thürlimann B., Huober J., Schönenberger A., Pagani O., Lüthi J., Simcock M., Giobbie-Hurder A., Berthod G., Genton C., Brauchli P., Aebi S.
Working group(s)
Swiss Group for Clinical Cancer Research (SAKK)
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
23
Number
6
Pages
1474-1481
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Abstract
BACKGROUND: The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We analyzed bone mineral density (BMD) in Swiss patients of the Breast International Group (BIG) 1-98 trial [treatment arms: A, tamoxifen (T) for 5 years; B, letrozole (L) for 5 years; C, 2 years of T followed by 3 years of L; D, 2 years of L followed by 3 years of T].
PATIENTS AND METHODS: Dual-energy X-ray absorptiometry (DXA) results were retrospectively collected. Patients without DXA served as control group. Repeated measures models using covariance structures allowing for different times between DXA were used to estimate changes in BMD. Prospectively defined covariates were considered as fixed effects in the multivariable models.
RESULTS: Two hundred and sixty-one of 546 patients had one or more DXA with 577 lumbar and 550 hip measurements. Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking. Treatment did not influence the occurrence of osteoporosis (T score < -2.5 standard deviation).
CONCLUSIONS: All aromatase inhibitor regimens reduced BMD. The sequential schedules were as detrimental for bone density as L monotherapy.
Keywords
Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bone Density/drug effects, Breast Neoplasms/drug therapy, Female, Hip/pathology, Hip/radiography, Humans, Lumbar Vertebrae/pathology, Lumbar Vertebrae/radiography, Middle Aged, Multivariate Analysis, Nitriles/administration & dosage, Osteoporosis/chemically induced, Osteoporosis/radiography, Postmenopause, Randomized Controlled Trials as Topic, Retrospective Studies, Tamoxifen/administration & dosage, Triazoles/administration & dosage
Pubmed
Web of science
Open Access
Yes
Create date
25/10/2011 9:23
Last modification date
25/09/2019 7:11
Usage data